Great findings from the PARACHUTE-HF trial, a study on heart failure caused by Chagas disease

During the ESC Congress 2025, held on September 1 in Madrid (Spain), Professor Renato Lopes (Durham, USA) presented PARACHUTE-HF, the first prospective and randomized clinical trial studying a treatment for chronic heart failure caused by Chagas disease.

On this study, researchers detected the reduction of an important prognostic biomarker for heart failure, which is associated with a lower risk of adverse cardiovascular events. Also, the study approaches to a more accurate clinical profile of patients suffering from Chagas heart failure among other cardiovascular diseases. So the results will help physicians in their decision-making regarding the treatment of heart failure in people affected by Chagas disease.

The study was funded by Novartis, in collaboration with the Brazilian Clinical Research Institute (BCRI), upon the request of the Latin American cardiology scientific community.

ESC Congress 2025 is an event focused on presenting the latest advances in cardiovascular science. It is organized by the World Heart Federation and the European Society of Cardiology, and held within the framework of the World Cardiology Congress.

Photos by: Cecilia Bahit & European Society of Cardiology